Pityriasis lichenoides (et varioliformis) acuta L41.0

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 02.02.2024

Dieser Artikel auf Deutsch

Synonym(s)

Mucha Habermann disease; Mucha-Habermann Syndrome; pityriasis lichenoides et varioliformis; pityriasis lichenoides et varioliformis acuta; PLEVA; PLUH

History
This section has been translated automatically.

Mucha, 1916; Habermann, 1925

Definition
This section has been translated automatically.

Often triggered by infectious allergies, inflammatory, self-limited, multiform disease with acute course, with preferential occurrence in the autumn and winter months. About 50% of the patients suffer from pruritus.

Many authors consider pityriasis lichenoides et varioliformis acuta as an acute course form of pityriasis lichenoides, so it can be assumed that they are different acute stages of one and the same entity.

Transitional forms between pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica (PLC) are possible. They are about 5% in larger collectives.

An extremely rare variant of PLEVA (50 cases in the literature to date) is considered to be the highly febrile ulceronecrotic course (pityriasis lichenoides with ulcers and hyperthermia = PLUH), which is associated with severe morbidity. Another name for this variant is FUMHD.

Occurrence/Epidemiology
This section has been translated automatically.

Incidence is 1:6000/1:12,000

Etiopathogenesis
This section has been translated automatically.

Unknown (immune complex vasculitis?).

Both PLC and PLEVA are lymphoproliferative T-cell disorders.

Suspected causes are infectious-allergic bacterial (hemolytic streptococci), drug-allergic, or viral(zoster virus, HHV-7, Epstein-Barr virus; SARS-CoV-2 (Mäkilä T et al. 2022), adenoviruses - Costa-Silva M et al. 2017; Horie C et al. 2018).

Occurred in isolated cases after vaccinations (Merlotto MR et al. 2020; Gunatheesan S et al. 2012, Castro BA et al. 2015), including after COVID-19 mRNA vaccination (Palmén J et al. (2022).

Proximity to cutaneous T-cell lymphomas is discussed (evidence of a monoclonal rearrangement of the T-cell receptor in > 50% of cases!).

The concept of immune complex vasculitis is based on the detection of immunoglobulins and complement in the junctional zone of the skin as well as in walls of dermal vessels.

Manifestation
This section has been translated automatically.

More frequent in the first two decades of life (6-18 years). Less frequent in infants.

Frequency peaks at 5 and 10 years;

Less frequently adults (middle age around 40 years) are affected.

Male sex preferred (m:w=3:1).

Localization
This section has been translated automatically.

Trunk, flexor sides of extremities; oral mucosa and capillitium remain free (differentiation from varicella).

Clinical features
This section has been translated automatically.

As in the "Heubner's star chart" (see varicella below), there is a very polymorphic, only moderately itchy, possibly burning, but often (in 50% of patients) completely asymptomatic exanthema.

Acute onset with 0.2-0.4 cm erythema, red or red-brown initially surface-smooth lichenoid papules. These rapidly disintegrate, with lesional formation of erosions, ulcers, and hemorrhagic crusts. Hemorrhagic vesicles are less common. The recurrent and relapsing course of the disease results in a coexistence of different efflorescences, with a correspondingly variegated (as in varicella) overall pattern.

Healing with formation of varioliform scars.

Passenger hyperpigmentation or leukoderma. Pruritus is present in most patients; fever and arthralgias are less common. About 30% of patients have no symptoms.

In rare cases, the disease can be highly febrile with severe general symptoms as well as sudden disseminated crusty ulcerations. Especially in adulthood, this complicating form of the disease (although extremely rare!) can also be lethal.

An extremely rare variant of PLEVA (50 cases in the literature so far) is the highly febrile ulceronecrotic course (pityriasis lichenoides with ulcers and hyperthermia = PLUH), which is associated with severe clinical symptoms.

Occasionally, skin changes indistinguishable from pityriasis lichenoides acuta et varioliformis are also observed in patients with lymphomatoid papulosis.

Laboratory
This section has been translated automatically.

Not relevant. Inflammation parameters (CRP, BSG) slightly increased.

Histology
This section has been translated automatically.

Lichenoid interface dermatitis with edema of the papillary body and exocytosis of lymphocytes and neutrophilic ganulocytes. The surface epithelium shows irregular acanthosis, a two-layered structure of the str. corneum with basket-weave-like orthokeratosis over a continuous parakeratosis zone.

Differently pronounced inter- and intracellular edema in the epidermis up to intraepidermal vesiculation; focal necrosis of the epidermis possible in the center of the lesion.

In the dermis, wedge-shaped, perivascular or interstitial infiltrate of CD8+ lymphocytes (occasionally also mixed with large lymphocytic irritant forms) and a few neutrophil granulocytes. T-cell clonality is often detectable. Leukocytoclastic vasculitis may develop if the clinical picture is pronounced, particularly in the case of ulceronecrotic progression.

Focal erythrocyte extravasations. Swelling of the endothelia, circumscribed erythrocyte diapedesis.

Immunohistology: Mostly C3 and/or IgM in the vascular walls of the upper dermal plexus.

Direct Immunofluorescence
This section has been translated automatically.

Non-specific.

Differential diagnosis
This section has been translated automatically.

  • Clinical Differentials:
    • Varicella: Clinical morphology may be very similar. Different pattern of involvement with involvement of oral mucosa and capillitium.
    • Köhlmeier-Degos disease: Rare, vasculitic systemic disease with diagnostic landmark clinic (disseminated papules with spatter-like atrophies in the center).
    • Drug ex anthem: No asynchronous polymorphism but rather monomorphic exanthem.
    • Syphilis: Syphilides are usually accompanied by LK swellings, the appearance rather monomorphic, frequently affecting palms and face. Serology is conclusive! Histology is conclusive (plasma cell-rich dermatitis).
    • Tuberculid, papulonecrotic: chronicity, evidence of active tuberculosis.
  • Histologic differential diagnoses:
    • Acute and subacute eczema: spongiosis, planar parakeratosis, no keratinocyte necrosis, in atopic eczema possible eosinophilia.
    • Fixed drug reaction: apoptotic keratinocytes, vacuolated junctional zone, satellite necrosis, perivascular lymphocytic infiltrate.
    • Psoriasis guttata: acanthosis, hyper- and parakeratosis with neutrophil inclusions, no keratinocyte necrosis; diffuse, also perivascular condensed lymphocytic infiltrate with neutrophil granulocytes, no erythrocyte extravasations, vigorous epidermotropism.
    • Pityriasis rosea: edema of papillary body, focal spongiosis, no apoptotic keratinocytes, superficial perivascular lymphocytic infiltrate, few eosinophils.
    • Early syphilis: interface dermatitis with psoriasiform epidermal reaction dense, band-like infiltrate in upper and middle dermis (lymphocytes, histiocytes and plasma cells; also epithelioid cell component. Extension of the infiltrate to the deep vascular plexus.
    • Köhlmeier-Degos disease:superficial and deep perivascular lymphocytic infiltrate. Epithelial necrosis, with wedge-shaped connective tissue necrosis.

Therapy
This section has been translated automatically.

Focus search and redevelopment.

External therapy
This section has been translated automatically.

Lotio alba, also glucocorticoid creams or lotions, e.g. Triamgalen cream/lotion, Betagalen cream/lotion, R123.

Radiation therapy
This section has been translated automatically.

Phototherapy can be used successfully. UVB- as well as UVA1-therapy and PUVA-therapy have proven to be successful. Recurrences after discontinuation of the radiation therapy are possible.

Internal therapy
This section has been translated automatically.

Good experience exists with erythromycin administration(3x500mg/day for 10 days), possibly in combination with glucocorticoids such as prednisolone (e.g. Decortin H initially 1mg/kgKG/day, rapid reduction).

For more severe pruritus, systemic antihistamine such as clemastine (e.g. Tavegil) 1-2 mg/day or desloratadine (e.g. Aerius) 5-10 mg/day p.o..

In the ulceronecrotic, febrile course, methotrexate (7.5-10.0 mg/m2 KO/week p.o. is recommended, possibly in combination with oral glucocorticoids(methylprednisolone 1-2 mg/kg bw/day).

Good response from TNF antagonists has been reported. IVIG (Marenco F et al. 2010) and extracorporeal photopheresis have also been used in individual cases.

Progression/forecast
This section has been translated automatically.

Frequent healing after relapse or recurrent course in an average period of 18 months (4-108 months; Ersoy-Evans S et al. 2007).

Transition to pityriasis lichenoides chronica is possible.

Only in rare cases of the febrile, ulceronecrotic form of progression can life-threatening complications develop.

Note(s)
This section has been translated automatically.

The PLEVA got its name because of the clinical similarity with the varicella

Literature
This section has been translated automatically.

  1. Costa-Silva M et al. (2017) Pityriasis lichenoides et varioliformis acuta associated with human herpesvirus 7. Actas Dermosifiliogr. doi: 10.1016/j.ad.2017.03.023.
  2. Castro BA et al (2015) Pityriasis lichenoides et varioliformis acuta after influenza vaccine. An Bras Dermatol 90(3 Suppl 1):181-184.
  3. de Unamuno Bustos B et al. (2014) Adult pityriasis lichenoides-like mycosis fungoides: a clinical variant of mycosis fungoides. Int J Dermatol 53:1331-1338.
  4. Ersoy-Evans S et al (2007) Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol 56:205-210.
  5. Gardlo K et al (2003) PUVA -therapy of severe pityriasis lichenoides et varioliformis acuta. Dermatologist 54: 984-985
  6. Gunatheesan S et al (2012) Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine. Australas J Dermatol 53:e76-78.
  7. Habermann R (1925) On the acute necrotizing subtype of pityriasis lichenoides (pityriasis lichenoides et varioliformis acuta). Dermatol Z 45: 42-48
  8. Horie C et al. (2018) Varicella zoster virus as a possible trigger for the development of pityriasis lichenoides et varioliformis acuta: retrospective analysis of our institutional cases. Clinical and experimental dermatology 43:703-707.
  9. Mäkilä T et al. (2022) Pityriasis lichenoides et varioliformis acuta after SARS-CoV-2 infection and relapse after vaccination. J Eur Acad Dermatol Venereol 36:e431-e433.
  10. Marenco F et al (2010) High-dose immunoglobulins and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. Dermatol Ther 23:419-422.
  11. Martinez-Escala ME et al (2014) γδ T cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T cell lymphomas. Br J Dermatol doi: 10.1111/bjd.13364.
  12. Merlotto MR et al (2020) Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine. An Bras Dermatol 95:259-260.
  13. Miyamoto T et al (2003) Febrile ulceronecrotic Mucha-Habermann disease: a case report and a review of the literature. J Clin Pathol 56: 795-797.
  14. Mucha V (1916) On a peculiar case close to parakeratosis variegata (Unna) or pityriasis lichenoides chronica (Neisser-Juliusberg). Arch Dermatol Syph 123: 586-592
  15. Nofal A et al (2016) Febrile ulceronecrotic Mucha-Habermann disease: proposed diagnostic criteria and therapeutic evaluation. Int J Dermatol 55:729-738.
  16. Palmén J et al (2022) Pityriasis lichenoides et varioliformis acuta following COVID-19 mRNA vaccination. J Eur Acad Dermatol Venereol 36:e327-e328.
  17. Weinberg JM et al (2002) The clonal nature ot pityriasis lichonides. Arch Dermatol 138: 1063-1067.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.